We are live on
!
Find out more
SCM
Stonepine Capital Management Portfolio holdings
AUM
$250M
1-Year Est. Return
77.6%
This Fund
S&P 500
This Quarter
Est. Return
+11.07%
1 Year Est. Return
+77.6%
3 Year Est. Return
+198.76%
5 Year Est. Return
+226.15%
10 Year Est. Return
+1,976.54%
AUM
$185M
AUM Growth
+$54.5M
(+42%)
Cap. Flow
+$54.7M
Cap. Flow
% of AUM
29.54%
Top 10 Holdings %
Top 10 Hldgs %
73.08%
Holding
35
New
14
Increased
10
Reduced
4
Closed
6
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CHMA
Chiasma, Inc. Common Stock
CHMA
|
+$16.2M |
| 2 |
AMYT
Amryt Pharma plc American Depositary Shares
AMYT
|
+$15.5M |
| 3 |
ADMS
Adamas Pharmaceuticals
ADMS
|
+$13.6M |
| 4 |
KALV
KalVista Pharmaceuticals
KALV
|
+$11.1M |
| 5 |
Gyre Therapeutics
GYRE
|
+$9.85M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Ligand Pharmaceuticals
LGND
|
+$32.4M |
| 2 |
AYTU BioPharma
AYTU
|
+$8.22M |
| 3 |
SCYNEXIS
SCYX
|
+$5.24M |
| 4 |
APEN
Apollo Endosurgery, Inc.
APEN
|
+$4.34M |
| 5 |
NEOS
Neos Therapeutics, Inc
NEOS
|
+$3.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 88.77% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
AGTC
26
DELISTED
Applied Genetic Technologies Corporation
AGTC
| $910K | 0.49% |
+179,511
| New | +$931K |
|
|
LKFT
27
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.78B
| $771K | 0.42% |
+10,000
| New | +$921K |
|
|
BWAY
28
Brainsway
BWAY
$611M
| $498K | 0.27% |
+110,362
| New | +$478K |
|
|
ONCS
29
DELISTED
OncoSec Medical Incorporated
ONCS
| $452K | 0.24% |
+4,308
| New | +$590K |
|
30
Cumberland Pharmaceuticals
CPIX
$100M
| – | – |
-188,703
| Closed | -$557K |
|
31
Eledon Pharmaceuticals
ELDN
$261M
| – | – |
-167,333
| Closed | -$2.58M |
|
|
32
Ligand Pharmaceuticals
LGND
$5.76B
| – | – |
-522,738
| Closed | -$32.4M |
|
|
33
SCYNEXIS
SCYX
$48.1M
| – | – |
-85,625
| Closed | -$5.24M |
|
34
VistaGen Therapeutics
VTGN
$9.89M
| – | – |
-16,667
| Closed | -$970K |
|
|
NEOS
35
DELISTED
Neos Therapeutics, Inc
NEOS
| – | – |
-4,962,657
| Closed | -$3.1M |
|
Similar funds
ER
FDDB
VM
PF
SCM
CWM
EWM
RA
Stonepine Capital Management's Q1 2021 Portfolio in Review
As of Q1 2021, Stonepine Capital Management held 35 positions worth $185M, up 42% from $131M the previous quarter. Its ten largest holdings account for 73% of the portfolio.
Stonepine Capital Management deployed $54.7M of net new capital in Q1 2021, opening 14 new positions and adding to 10 existing holdings. Its largest new stake was KalVista Pharmaceuticals: 422,310 shares worth $10.8M.
By sector, the portfolio is most concentrated in Healthcare at 89% of assets, down from 97% a quarter earlier.
On the sell side, the largest reduction was AYTU BioPharma, an estimated $8.22M trimmed.
- Stonepine Capital Management's largest Q1 2021 buy was KalVista Pharmaceuticals: 422,310 shares worth $10.8M.
- Stonepine Capital Management added most to Chiasma, Inc. Common Stock in Q1 2021, an estimated $16.2M increase.
- Stonepine Capital Management's biggest Q1 2021 reduction was AYTU BioPharma, cutting an estimated $8.22M.
- Stonepine Capital Management fully exited Ligand Pharmaceuticals in Q1 2021, selling an estimated $32.4M.
- Stonepine Capital Management's ten largest holdings make up 73% of its $185M portfolio in Q1 2021.
- Stonepine Capital Management opened 14 new positions and closed 6 in Q1 2021.
- Stonepine Capital Management's portfolio value rose 42% quarter-over-quarter to $185M.
Based on Stonepine Capital Management's 13F filing for Q1 2021, filed 14 May 2021.